#United States #Innovations #New York #Galien Foundation #Prix Galien

The 2025 Prix Galien USA Awards Nominees

On August 11, 2025, the Galien Foundation announced the nominees for the prestigious 2025 Prix Galien USA Awards. Set to take place on October 30, 2025, at the American Museum of Natural History in New York City, these awards celebrate groundbreaking advancements in the realm of health care. The focus this year highlights innovations in three distinct categories: Best Biotechnology Product, Best Pharmaceutical Product, and Best Product for Rare/Orphan Diseases.

The Prix Galien Foundation is recognized globally for its commitment to honoring those pioneering advancements within life sciences. This year, the nominees have been handpicked for their remarkable contributions to improving human health. According to Dr. Michael Rosenblatt, Chair of the awards committee and a former dean at Tufts University School of Medicine, it’s an honor to spotlight these innovations as a means of tackling significant global health challenges. Dr. Rosenblatt's continued dedication to medical research and innovation resonates through his involvement at the Galien Foundation, showcasing his efforts to inspire excellence within the healthcare sector.

The selection process for nominees is stringent. To qualify, candidates must possess U.S. Food and Drug Administration (FDA) approval to market their products within the past five years. Only those demonstrating exceptional promise in enhancing public health are considered. Notably, sales figures do not influence the nominating committee; the primary focus rests on the scientific quality and health impacts of the products.

Nominees Breakdown

The awards feature an impressive array of nominees:

Best Biotechnology Product (16 nominees)

• - Amgen Inc.: IMDELLTRA®
• - Arcutis Biotherapeutics, Inc.: ZORYVE®
• - AstraZeneca and Sanofi: Beyfortus®
• - Bavarian Nordic: VIMKUNYA™
• - Catalyst Pharmaceuticals: Agamree®
• - Gilead Sciences: Sunlenca®
• - Johnson & Johnson: TECVAYLI™
• - Johnson & Johnson: TALVEY™
• - Johnson & Johnson and Legend Biotech USA Inc.: CARVYKTI®
• - Merck & Co Inc.: CAPVAXIVE™
• - MGI Tech: DNBSEQ-T20
• - Novartis Pharmaceuticals Corporation: SCEMBLIX®
• - Pfizer Inc.: ABRYSVO®
• - Pfizer Inc./Astellas: PADCEV®
• - Regeneron and Sanofi: Dupixent®
• - Signet Therapeutics: SIGX1094R

Best Pharmaceutical Product (18 nominees)

• - AbbVie: ELAHERE®
• - Ardelyx, Inc.: XPHOZAH®
• - Biogen, Sage Therapeutics: ZURZUVAE®
• - Bristol Myers Squibb: COBENFY™
• - Eisai and Biogen Inc.: LEQEMBI®
• - Eli Lilly and Company: Kisunla™
• - Genentech, A Member of the Roche Group: VABYSMO™
• - Genentech, A Member of the Roche Group: PHESGO®
• - Gilead Sciences: Yeztugo®
• - Idorsia Pharmaceuticals Ltd.: TRYVIO™
• - Incyte: Opzelura®
• - Innoviva Specialty Therapeutics, Inc.: ZEVTERA®
• - Innoviva Specialty Therapeutics, Inc.: XACDURO®
• - Merck & Co. Inc.: WINREVAIR™
• - Novartis Pharmaceuticals Corporation: PLUVICTO®
• - Pfizer Inc.: ZAVZPRET™
• - Phathom Pharmaceuticals: VOQUEZNA®
• - Sanofi-Aventis U.S. LLC: Tzield®

Best Product for Rare/Orphan Diseases (13 nominees)

• - Biogen Inc.: SKYCLARYS®
• - Biogen Inc. and Ionis Pharmaceuticals: QALSODY®
• - Ionis Pharmaceuticals, Inc.: TRYNGOLZA™
• - Jazz Pharmaceuticals, Inc.: Ziihera®
• - Marinus Pharmaceuticals, Inc.: ZTALMY®
• - Merus: Bizengri®
• - Novo Nordisk, Inc.: Alhemo®
• - PTC Therapeutics: KEBILIDI™
• - Servier Pharmaceuticals: VORANIGO®
• - SpringWorks Therapeutics, Inc.: OGSIVEO®
• - Syndax Pharmaceuticals, Inc.: REVUFORJ®
• - X4 Pharmaceuticals, Inc.: XOLREMDI®
• - Zevra Therapeutics, Inc.: MIPLYFFA®

The Ceremony Ahead

As the excitement builds toward the awards ceremony, Bruno Cohen, Chairman of the Galien Foundation, emphasizes the importance of these innovations indicating a vibrant future for the life sciences industry. The committee, comprised of eminent experts, including three Nobel Laureates, is poised to evaluate these stellar innovations and celebrate their contributions to society. This event serves not just as an awards ceremony but as a testament to the unyielding efforts towards improving human health.

About the Galien Foundation

Established to recognize excellence in healthcare innovations, the Galien Foundation is dedicated to supporting the development of groundbreaking therapies that can save lives. The foundation's endeavors track back to its honoring of the father of pharmacology, Galen, with the aim to propel forward-thinking treatments and technologies into the global healthcare narrative. For more information, visit Galien Foundation.

• ---